Demonstration Formulary
1 Gastro-intestinal system
fgsdfgsdfgs
01-05-03 Vedolizumab
| Vedolizumab Entyvio® |
|
Restricted
|
Specialist use only in line with NICE guidance below |
 NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
|
Links
- NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
- NICE TA134: Infliximab for psoriasis
- NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
- NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40)
- NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40)
- NICE TA329: Infiximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA329:Infliximab,adalimumab,and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
- NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
- NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
- NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
- NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
- UKMI Q&A: Can patients drink alcohol whilst taking long-term low-dose methotrexate?
- UKMI Q&A: What is the clinical significance of the interaction between methotrexate and penicillins? (Oct13)